Introduction; Contents; Chapter 1: Pharmacogenetics of the Efficacy of Antipsychotic Drugs in Schizophrenia; 1.1 Introduction; 1.1.1 Pharmacogenetics of Antipsychotic Efficacy; 1.1.2 Clinical Response Phenotypes; 1.1.3 Research Strategies; 1.2 Pharmacogenetic and Pharmacogenomic Findings; 1.2.1 Candidate Gene Studies; 1.2.1.1 Findings Related to Antipsychotic Efficacy; Findings in Targeted Neurotransmitters and Transporters; Findings in Metabolic Enzymes; Others; 1.2.1.2 Findings Related to Antipsychotic-Induced Side Effects; Findings in Targeted Neurotransmitter Receptors and Transporters

Findings in Metabolic EnzymesOthers; 1.2.2 Genome-Wide Association Studies (GWAS); 1.2.2.1 Findings Related to Antipsychotic Efficacy; 1.2.2.2 Findings Related to Antipsychotic Side Effects; 1.3 Clinical Applications and Benefits of Pharmacogenetic Interventions; 1.3.1 Pharmacogenetic Findings as Biomarkers of Clinical Outcome; 1.3.2 Pharmacogenetic Tests for Prediction of Antipsychotic Response; 1.4 Conclusions; References; Chapter 2: Pharmacogenetics of Serious Antipsychotic Side Effects; 2.1 Background; 2.2 Common Side Effects; 2.2.1 Tardive Dyskinesia; 2.2.1.1 Drug Metabolism Genes

2.2.1.2 Neurotransmitter GenesDopamine System Genes; Serotonin System Genes; 2.2.1.3 Oxidative Stress Genes; 2.2.1.4 Other Genes; The Brain-Derived Neurotrophic Factor (BDNF); Cannabinoid Receptor 1 (CNR1); Dipeptidyl Peptidase-Like Protein 6 (DPP6); Heparan Sulphate Proteoglycan 2 (HSPG2), Perlecan; 2.2.2 Antipsychotic-Induced Weight Gain (AIWG); 2.2.2.1 Neurotransmitter Genes; Serotonin System Genes; Dopamine System Genes; 2.2.2.2 Leptin and Leptin Receptor; 2.2.2.3 The Melanocortin 4 Receptor (MC4R); 2.2.2.4 The Cannabinoid Receptor 1 (CNR1) and the Neuropeptide Y (NPY) Genes

2.2.2.5 Mitochondrial Genes2.2.2.6 Other Genes; 2.2.3 Clozapine-Induced Agranulocytosis (CIA); 2.3 Summary; References; Chapter 3: Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs; 3.1 Introduction; 3.1.1 Candidate Gene Studies; 3.1.1.1 Monoaminergic System; Serotonin Transporter; Serotonin Receptors; Enzymes Responsible for Monoamine Metabolism; 3.1.1.2 Glutamatergic System; 3.1.1.3 Neuroplasticity; 3.1.1.4 Inflammation; Cytokines; HPA Axis; 3.1.1.5 Antidepressant Pharmacokinetics; Cytochrome P450 Genes; ABCB1 Gene; 3.1.2 Genome-Wide Association Studies (GWAS)

3.2 Clinical Applicability3.3 Conclusion; References; Chapter 4: Genomic Studies of Treatment Resistance in Major Depressive Disorder; 4.1 Background and Motivation; 4.2 Rationale for Genetic Investigation; 4.3 Association Studies of TRD; 4.4 Treatment Outcomes in TRD Cohorts; 4.5 Clinical Status; 4.6 Challenges and Future Directions; References; Chapter 5: Complementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression; 5.1 Introduction; 5.2 Blood-Based Biomarkers; 5.2.1 Inflammation; 5.2.1.1 Predicting Treatment Response; 5.2.2 HPA Axis